CEO Todd Zavodnick (Dermavant)
February 18, 2021 08:25 AM EST
R&D

With long-term da­ta in hand, Vivek Ra­maswamy's Der­ma­vant team dash­es to the goal line with top­i­cal pso­ri­a­sis con­tender

Nicole DeFeudis

Editor

Months af­ter tout­ing pos­i­tive da­ta from two piv­otal Phase II­Is, Vivek Ra­maswamy’s Der­ma­vant team is back with long-term da­ta to back its pso­ri­a­sis can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times